Application of ED-optimality to screening experiments for analgesic compounds in an experimental model of neuropathic pain

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 39, Issue 6, 2012, Pages 673-681

  Taneja, A ^a   Nyberg, J ^b   De Lange, E C M ^a   Danhof, M ^a   Della Pasqua, O ^a,c  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UPPSALA UNIVERSITY   (Sweden)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Drug development; Gabapentin; Logistic regression; Neuropathic pain; Optimal design; PKPD modelling

Indexed keywords

GABAPENTIN; PLACEBO;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL PROTOCOL; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG POTENCY; DRUG SCREENING; EXPERIMENTAL STUDY; FEASIBILITY STUDY; LOGISTIC REGRESSION ANALYSIS; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; RAT; SIMULATION; STOCHASTIC MODEL; SYSTEMATIC ERROR;

AMINES; ANALGESICS; ANIMALS; CYCLOHEXANECARBOXYLIC ACIDS; DOUBLE-BLIND METHOD; DRUG EVALUATION, PRECLINICAL; FREUND'S ADJUVANT; GAMMA-AMINOBUTYRIC ACID; LOGISTIC MODELS; MODELS, BIOLOGICAL; NEURALGIA; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84880754509     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-012-9278-9     Document Type: Article

References (25)

1. Agresti A (1999) Modelling ordered categorical data: recent advances and future challenges. Stat Med 18:2191-2207 (Pubitemid 29423489)
2. Backonja M, Woolf CJ (2010) Future directions in neuropathic pain therapy: closing the translational loop. Oncologist 15(Suppl. 2):24-29
3. Blackburn-Munro G (2004) Pain-like behaviours in animals - how human are they? Trends Pharmacol Sci 25:299-305 (Pubitemid 38692421)
4. Bouillon-Pichault M, Jullien V, Bazzoli C, Pons G, Tod M (2011) Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4. J Pharmacokinet Pharmacodyn 38:25-40
5. Danhof M, Lange EC, Ploeger BA, Voskuyl RA, Della Pasqua O (2008) Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci 29:186-191
6. D'Argenio DZ (1981) Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 9:739-756 (Pubitemid 12184821)
7. Dodds MG, Hooker AC, Vicini P (2005) Robust population pharmacokinetic experiment design. J Pharmacokinet Pharmacodyn 32:33-64 (Pubitemid 41586840)
8. Gilron I, Coderre TJ (2007) Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs 12:113-126 (Pubitemid 46490733)
9. Hooker AC, Foracchia M, Dodds MG, Vicini P (2003) An evaluation of population D-optimal designs via pharmacokinetic simulations. Ann Biomed Eng 31:98-111
10. Huntjens DR, Danhof M, Della Pasqua O (2005) Pharmacokinetic- pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology 44:846-859 (Pubitemid 41511177)
11. Huntjens DR, Spalding DJ, Danhof M, Della Pasqua O (2009) Differences in the sensitivity of behavioural measures of pain to the selectivity of cyclo-oxygenase inhibitors. Eur J Pain 13:448-457
12. Joshi SK, Honore P, Hernandez G, Schmidt R, Gomtsyan A et al (2009) Additive antinociceptive effects of the selective Nav1.8 blocker A-803467 and selective TRPV1 antagonists in rat inflammatory and neuropathic pain models. J Pain 10:306-315
13. Le Bars D, Gozariu M, Cadden SW (2001) Animal models of nociception. Pharmacol Rev 53:597-652 (Pubitemid 33136239)
14. Nestorov I, Graham G, Duffull S, Aarons L, Fuseau E et al (2001) Modeling and simulation for clinical trial design involving a categorical response: a phase II case study with naratriptan. Pharm Res 18:1210-1219 (Pubitemid 32900408)
15. Nyberg J, Karlsson MO, Hooker AC (2009) Simultaneous optimal experimental design on dose and sample times. J Pharmacokinet Pharmacodyn 36:125-145
16. Ogungbenro K, Aarons L (2007) Design of population pharmacokinetic experiments using prior information. Xenobiotica 37:1311-1330 (Pubitemid 350035531)
17. Ogungbenro K, Aarons L (2010) Optimal design of pharmacokinetic studies. Basic Clin Pharmacol Toxicol 106:250-255
18. Pang MH, Kim Y, Jung KW, Cho S, Lee DH (2012) A series of case studies: practical methodology for identifying antinociceptive multi-target drugs. Drug Discov Today 17:425-434
19. R Development Core Team (2010) R: a language and environment for statistical computing, ed. R Foundation for statistical computing, R Foundation for statistical computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org
20. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512
21. Stewart BH, Kugler AR, Thompson PR, Bockbrader HN (1993) A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 10:276-281 (Pubitemid 23041744)
22. Taneja A, Di Iorio VL, Danhof M, Della Pasqua O (2012) Translation of drug effects from experimental models of neuropathic pain and analgesia to humans. Drug Discov Today 17:837-849
23. Tod M, Rocchisani JM (1997) Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics. J Pharmacokinet Biopharm 25:515-537 (Pubitemid 28186450)
24. Walker K, Fox AJ, Urban LA (1999) Animal models for pain research. Mol Med Today 5:319-321 (Pubitemid 29302680)
25. Schoemaker RC, van Gerven JM, Cohen AF (1998) Estimating potency for the Emax model without attaiing maximal effects. J Pharmacokinet Biopharm 26:581-593 (Pubitemid 29157784)